AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference

Company Overview - AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs [2] - The company's initial candidate is epetraborole, which is being studied as a once-daily, oral treatment for patients with nontuberculous mycobacteria (NTM) lung disease [2] - NTM lung disease is a rare, chronic, and progressive infectious disease caused by mycobacteria, leading to irreversible lung damage and potential fatality [2] Event Announcement - Eric Easom, Co-Founder, President and CEO of AN2 Therapeutics, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference [1] - The presentation is scheduled for February 14, 2024, at 10:40 am ET [1] - A webcast of the presentation will be available on the Investors section of the AN2 Therapeutics website, with an archived replay accessible for at least 30 days following the event [1]